#DLL3
#IDYA IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential…

https://www.stocktitan.net/news/IDYA/ideaya-biosciences-announces-successful-us-fda-type-c-meeting-on-j9nv9004jjro.html?utm_source=stocktitan-bluesky&utm_medium=social
IDEAYA Biosciences Announces Successful US FDA Type C Meeting on Phase 2/3 Registrational Trial Designs to Support Potential Accelerated and Full Approval for IDE849, a Potential Best-in-Class DLL3 TOP1 ADC, in Neuroendocrine Carcinomas
IDEAYA Biosciences (Nasdaq: IDYA) outlined IDE849 registration plans for previously treated neuroendocrine carcinomas following a Type C FDA meeting.The company plans an approximately 90-patient gastroenteropancreatic neuroendocrine carcinoma cohort targeting potential accelerated approval, using confirmed response rate assessed by blinded independent review. A planned randomized Phase 3 trial across multiple neuroendocrine carcinoma subtypes would assess progression-free survival for accelerated approval and overall survival for full approval. IDEAYA targets starting both studies and a Phase 3 trial after Imdelltra in extensive-stage small cell lung cancer by year-end 2026.Partner Phase 1 data showed a 52.6% response rate among 19 patients, with 36.8% confirmed responses. In the separate global Phase 1/2 trial, severe treatment-related adverse event rates were 5% and 22.2% at the respective expansion doses.
www.stocktitan.net
November 16, 2026 at 9:05 PM
Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab
Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab
Nomura et al. identify a neuroimmune mechanism of resistance to DLL3 × CD3-directed T cell engager and ICB therapy in SCLCs and LCNECs. They show that tumor-derived serotonin programs immunosuppressive macrophages through HTR7 signaling, dampening antitumor T cell responses and limiting immunotherapy efficacy, while revealing a therapeutically actionable vulnerability.
dlvr.it
November 9, 2026 at 7:51 PM
Zymeworks has licensed its ZW209 trispecific to Roche for $95m upfront plus up to $718m in milestones. The programme targets DLL3 in T cell engagers. Full story:
Zymeworks licenses ZW209 trispecific T cell engager to Roche
Zymeworks will receive $95 million in near-term payments and up to $718 million in milestones from Roche for global rights to its DLL3-targeting
thebiotechtimes.com
November 6, 2026 at 8:01 PM
CRV Science Wiki
🧬 Notch Signaling Pathway — The Notch signaling pathway is a conserved metazoan juxtacrine (cell-contact-dependent) signaling mechanism in which both the transmembrane receptors (Notch1–4 in mammals) and their canonical transme…

https://crvscience.com/wiki/notch-signaling-pathway
CRV Science Wiki 🧬 Notch Signaling Pathway — The Notch signaling pathway is a conserved metazoan juxtacrine (cell-contact-dependent) signaling mechanism in which both the transmembrane receptors (Notch1–4 in mammals) and their canonical transmembrane ligands (Delta-like [DLL1, DLL3, DLL4] and Jag…
crvscience.com
November 8, 2026 at 1:40 AM
#MOLN Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026

https://www.stocktitan.net/news/MOLN/molecular-partners-to-present-on-dll3-targeting-radio-dar-pin-mp0712-ivuzgmyyjgtn.html?utm_source=stocktitan-bluesky&utm_medium=social
Molecular Partners to Present on DLL3-Targeting Radio-DARPin MP0712 at 2026 SNMMI Theranostics Conference and NACLC 2026
Molecular Partners (MOLN) will present on its cancer treatment candidate MP0712 at scientific conferences on November 7 and December 5, 2026. Co-developed with Orano Med, MP0712 targets DLL3, a protein expressed by certain tumors.The November 7 oral presentation at the SNMMI Theranostics Conference in Bethesda will discuss target expression and advancing MP0712 into clinical testing. The December 5 poster at the North America Conference on Lung Cancer in Scottsdale will cover initial dose-escalation data from a first-in-human Phase 1/2a study in patients with small cell lung cancer and other DLL3-expressing solid tumors. Presentations will be available on the company website afterward.
www.stocktitan.net
November 5, 2026 at 6:00 AM
👀 Excited about how lung cancer data from #ESMO2026 could influence clinical practice? So are we! @myesmo.bsky.social #lcsm #oncology

Sign up to read exclusive expert insights on the top data from the meeting! ➡️ www.onclive.com/view/dll3-ta...
November 5, 2026 at 1:28 PM
Targeting DLL3 in refractory extrapulmonary neuroendocrine carcinomas (EP-NECs): New Phase 1b/2 data presented at #NANETS2026 shows promising activity with the novel ADC zocilurtatug pelitecan in post-platinum disease🔬

Read more! https://bit.ly/4sTbJmc
November 6, 2026 at 8:22 PM
🥼 Zymeworks, a #VancouverBiotech, has entered into a global license and collaboration agreement with Roche for the research, development, and commercialization of ZW209, a #TCell engager targeting DLL3. The agreement is worth up to $813M.

Learn more: https://bit.ly/4sCx9Ux
November 3, 2026 at 7:59 PM
Allogene (#$ALLO) will present at SITC (Phoenix, Nov. 5-6): TRAVERSE renal cell carcinoma clinical experience plus a preclinical DLL3/CD70 dual CAR T poster. No new clinical data.

prismmarketview.com/allogene-to-...
Allogene to Highlight Clinical Progress and Next-Generation CAR T Research at SITC
Key Points Allogene will deliver two invited presentations and a preclinical poster at the SITC Annual Meeting in Phoenix. Presentations will cover clin
prismmarketview.com
November 3, 2026 at 4:19 PM
Aggressive #CervicalCancer evades immune defenses.
This study identifies DLL3 as a driver of #tumor progression and T-cell exhaustion in neuroendocrine cervical carcinoma, revealing a promising therapeutic target. @fudanuni_official
#GenesAndDiseases: doi.org/10.1016/j.ge...
October 31, 2026 at 2:02 PM
#Amgen has revealed data that it hopes will move its DLL3-targeting T-cell engager #Imdelltra into the first-line setting in small cell lung cancer (#SCLC) as a #combinationregimen with #AstraZeneca's #Imfinzi.

pharmaphorum.com/news/esmo26-...
October 25, 2026 at 6:49 PM
Two drugs hoping to muscle in on Amgen's first-to-market DLL3-targeting drug Imdelltra – from #ZaiLab and #Ideaya – have new trial readouts at #ESMO26. #lungcancer

pharmaphorum.com/news/esmo26-...
October 24, 2026 at 12:09 PM
🚨 JUST IN: $ZYME
Zymeworks licenses DLL3 T-cell engager ZW209 to Roche for $55M upfront, up to $758M in milestones

#SEC #stocks #investing #ZYME #Mergers
🔗 secwatch.observer
October 23, 2026 at 10:11 AM
Après environ 16 mois, « l’association du tarlatamab et du durvalumab a permis une réduction de 58 % du risque de décès ». Un an après le début du traitement, 79 % des patients traités par l’association tarlatamab-durvalumab étaient en vie, versus 53 % de ceux qui recevaient le durvalumab seul.
October 26, 2026 at 11:26 AM
Don't miss posters today at #ESMO26: Salomon Tendler will present data showing that DLL3 PET identifies neuroendocrine differentiation and tumor heterogeneity in advanced prostate cancer. @mskcancercenter.bsky.social

📅 October 23 | 3:15 p.m. CEST
October 23, 2026 at 12:00 PM
Online Now: Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab
Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab
Nomura et al. identify a neuroimmune mechanism of resistance to DLL3 × CD3-directed T cell engager and ICB therapy in SCLCs and LCNECs. They show that tumor-derived serotonin programs immunosuppressive macrophages through HTR7 signaling, dampening antitumor T cell responses and limiting immunotherapy efficacy, while revealing a therapeutically actionable vulnerability.
dlvr.it
October 23, 2026 at 6:51 PM
シグナル分子の1つであるDLL3を高発現する肺神経内分泌がん細胞ではセロトニンが作られておりマクロファージのはたらきを抑える。

さらに、セロトニン産生を抑えるとがん免疫療法の効果が高まった in mice.

肺神経内分泌がんがセロトニンを利用して抗腫瘍免疫応答を抑える仕組みを解明―免疫療法への治療抵抗性の克服につながることが期待―
pod.ncc.go.jp/jp/informati...
肺神経内分泌がんがセロトニンを利用して抗腫瘍免疫応答を抑える仕組みを解明
国立がん研究センターのホームページです。
pod.ncc.go.jp
October 24, 2026 at 3:34 AM
$IDYA Oct 23, 2026: IDEAYA released updated Phase 1 data from partner Hengrui for IDE849, its DLL3 ADC: in previously treated SCLC, 68.3% response and 14.7 months median overall survival; 17.4 months in second line (51 pts).

https://www.merlintrader.com/ideaya-biosciences-stock-hub/
IDEAYA $IDYA Stock Hub: Darovasertib And $1.24B Of Cash
IDEAYA ($IDYA) hub: the darovasertib registrational path in uveal melanoma, $1.24B of cash, the rising burn, ESMO in October and the risks.
www.merlintrader.com
October 23, 2026 at 12:05 PM
$ZYME Oct 23, 2026: Zymeworks licensed ZW209, its DLL3 trispecific T-cell engager, to Roche worldwide: $55M upfront, $40M at Phase 1b start, up to $718M in milestones, tiered royalties up to mid-teens. Roche funds Phase 1a. Subject to HSR clearan...

https://www.merlintrader.com/zymeworks-stock-hub/
Zymeworks ($ZYME) Stock Hub: Ziihera Royalties, YUPELRI
Zymeworks (ZYME) stock hub: the $250M Ziihera milestone, Jazz royalties of 10-20%, the completed Theravance acquisition and 2026 guidance of $278-292M.
www.merlintrader.com
October 23, 2026 at 12:10 PM
(WO2026208730A1) discloses DLL3-targeted cyclic peptide radioligands for imaging (^68Ga) and therapy (^177Lu, ^225Ac). Kelun-Biotech extends its conjugate strategy beyond ADCs into preclinical theranostics; tumour-to-kidney/marrow dosimetry versus antibody-based radioligands remains key.
October 19, 2026 at 5:46 AM
The authors included RRIDs in their in Molecular Cancer Therapeutics paper! We value the author's support of reproducibility. #RRID #accelerateopenscience #OpenScience
VHH-based CAR-T cells targeting DLL3 show high efficacy in small-cell lung cancer models.
Read the full paper: VHH-based CAR-T cells targeting DLL3 show high efficacy in small-cell lung cancer models.
doi.org
October 18, 2026 at 7:02 AM